EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis

Krishna Vamsy Polepalli, Prarath Roshni, Sushma Moka, Rinita Reddi, Mahesh Manish, Vineeth Potluri

Digestive Diseases · 09.11.2026

DOI: 10.1159/ddi/acnag020 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Digestive Diseases, online erschienen am 09.11.2026. Verfasst von Krishna Vamsy Polepalli und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively.

Methods

In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis.

Results

Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09–4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01–1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI −55.24 to −37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97–6.49). ALT (MD −20.38 IU/L, 95% CI −33.00 to −7.75), AST (MD −18.80 IU/L), body weight (MD −4.36%) and systolic blood pressure (MD −5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent.

Conclusions

Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.

Zitieren

APA

Polepalli, K. V., Roshni, P., Moka, S., Reddi, R., Manish, M., & Potluri, V. (2026). GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis. Digestive Diseases. https://doi.org/10.1159/ddi/acnag020

Vancouver

Polepalli KV, Roshni P, Moka S, Reddi R, Manish M, Potluri V. GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis. Digestive Diseases. 2026. doi:10.1159/ddi/acnag020

BibTeX
@article{Polepalli2026,
  author = {Polepalli, Krishna Vamsy and Roshni, Prarath and Moka, Sushma and Reddi, Rinita and Manish, Mahesh and Potluri, Vineeth},
  title = {GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis},
  journal = {Digestive Diseases},
  year = {2026},
  doi = {10.1159/ddi/acnag020}
}
Kostenlos starten →